Q-T interval (QTc) in patients with cirrhosis: relation to vasoactive peptides and heart rate.

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningfagfællebedømt

Standard

Q-T interval (QTc) in patients with cirrhosis: relation to vasoactive peptides and heart rate. / Henriksen, Jens Henrik; Gülberg, V.; Fuglsang, Stefan; Schifter, Søren; Bendtsen, Flemming; Gerbes, A.L.; Møller, Søren.

I: Scandinavian Journal of Clinical & Laboratory Investigation, Bind 67, Nr. 6, 2007, s. 643-653.

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningfagfællebedømt

Harvard

Henriksen, JH, Gülberg, V, Fuglsang, S, Schifter, S, Bendtsen, F, Gerbes, AL & Møller, S 2007, 'Q-T interval (QTc) in patients with cirrhosis: relation to vasoactive peptides and heart rate.', Scandinavian Journal of Clinical & Laboratory Investigation, bind 67, nr. 6, s. 643-653. https://doi.org/10.1080/00365510601182634

APA

Henriksen, J. H., Gülberg, V., Fuglsang, S., Schifter, S., Bendtsen, F., Gerbes, A. L., & Møller, S. (2007). Q-T interval (QTc) in patients with cirrhosis: relation to vasoactive peptides and heart rate. Scandinavian Journal of Clinical & Laboratory Investigation, 67(6), 643-653. https://doi.org/10.1080/00365510601182634

Vancouver

Henriksen JH, Gülberg V, Fuglsang S, Schifter S, Bendtsen F, Gerbes AL o.a. Q-T interval (QTc) in patients with cirrhosis: relation to vasoactive peptides and heart rate. Scandinavian Journal of Clinical & Laboratory Investigation. 2007;67(6):643-653. https://doi.org/10.1080/00365510601182634

Author

Henriksen, Jens Henrik ; Gülberg, V. ; Fuglsang, Stefan ; Schifter, Søren ; Bendtsen, Flemming ; Gerbes, A.L. ; Møller, Søren. / Q-T interval (QTc) in patients with cirrhosis: relation to vasoactive peptides and heart rate. I: Scandinavian Journal of Clinical & Laboratory Investigation. 2007 ; Bind 67, Nr. 6. s. 643-653.

Bibtex

@article{9aa3fc511d864c068d128c777a913433,
title = "Q-T interval (QTc) in patients with cirrhosis: relation to vasoactive peptides and heart rate.",
abstract = "OBJECTIVE: Prolonged Q-T interval (QT) has been reported in patients with cirrhosis who also exhibit profound abnormalities in vasoactive peptides and often present with elevated heart rate (HR). The aim of this study was to relate QT to the circulating level of endothelins (ET-1 and ET-3) and calcitonin gene-related peptide (CGRP) in patients with cirrhosis. In addition, we studied problems with HR correction of QT. MATERIAL AND METHODS: Forty-eight patients with cirrhosis and portal hypertension were studied during a haemodynamic investigation. Circulating levels of ETs and CGRP were determined by radioimmunoassays. Correction of QT for HR above 60 beats per min was performed using the methods described by Bazett (QT(C)) and Fridericia (QT(F)). RESULTS: Prolonged QT(C) (above 440 ms), found in 56% of the patients, was related to the presence of significant portal hypertension and liver dysfunction (p < 0.05 to 0.001), but not to elevated ET-1, ET-3 or CGRP. When corrected according to Bazett, QT(C) showed no significant relation to differences in HR between patients (r = 0.07, ns). QTF showed some undercorrection of HR (r = -0.36; p < 0.02). During HR variation in the individual patient, QT(C) revealed a small but significant overcorrection (2.6 ms per heartbeat per min; p < 0.001). This value was significantly (p < 0.02) smaller with QTF (1.2 ms per heartbeat per min). CONCLUSIONS: The prolonged QT(C) in cirrhosis is related to liver dysfunction and the presence of portal hypertension, but not to the elevated powerful vasoconstrictor (ET-1) or vasodilator (CGRP, ET-3) peptides. The problems with correction of the QT for elevated HR in cirrhosis are complex, and the lowest HR should be applied for determination of the QT.",
author = "Henriksen, {Jens Henrik} and V. G{\"u}lberg and Stefan Fuglsang and S{\o}ren Schifter and Flemming Bendtsen and A.L. Gerbes and S{\o}ren M{\o}ller",
year = "2007",
doi = "http://dx.doi.org/10.1080/00365510601182634",
language = "English",
volume = "67",
pages = "643--653",
journal = "Scandinavian Journal of Clinical & Laboratory Investigation",
issn = "0036-5513",
publisher = "Taylor & Francis",
number = "6",

}

RIS

TY - JOUR

T1 - Q-T interval (QTc) in patients with cirrhosis: relation to vasoactive peptides and heart rate.

AU - Henriksen, Jens Henrik

AU - Gülberg, V.

AU - Fuglsang, Stefan

AU - Schifter, Søren

AU - Bendtsen, Flemming

AU - Gerbes, A.L.

AU - Møller, Søren

PY - 2007

Y1 - 2007

N2 - OBJECTIVE: Prolonged Q-T interval (QT) has been reported in patients with cirrhosis who also exhibit profound abnormalities in vasoactive peptides and often present with elevated heart rate (HR). The aim of this study was to relate QT to the circulating level of endothelins (ET-1 and ET-3) and calcitonin gene-related peptide (CGRP) in patients with cirrhosis. In addition, we studied problems with HR correction of QT. MATERIAL AND METHODS: Forty-eight patients with cirrhosis and portal hypertension were studied during a haemodynamic investigation. Circulating levels of ETs and CGRP were determined by radioimmunoassays. Correction of QT for HR above 60 beats per min was performed using the methods described by Bazett (QT(C)) and Fridericia (QT(F)). RESULTS: Prolonged QT(C) (above 440 ms), found in 56% of the patients, was related to the presence of significant portal hypertension and liver dysfunction (p < 0.05 to 0.001), but not to elevated ET-1, ET-3 or CGRP. When corrected according to Bazett, QT(C) showed no significant relation to differences in HR between patients (r = 0.07, ns). QTF showed some undercorrection of HR (r = -0.36; p < 0.02). During HR variation in the individual patient, QT(C) revealed a small but significant overcorrection (2.6 ms per heartbeat per min; p < 0.001). This value was significantly (p < 0.02) smaller with QTF (1.2 ms per heartbeat per min). CONCLUSIONS: The prolonged QT(C) in cirrhosis is related to liver dysfunction and the presence of portal hypertension, but not to the elevated powerful vasoconstrictor (ET-1) or vasodilator (CGRP, ET-3) peptides. The problems with correction of the QT for elevated HR in cirrhosis are complex, and the lowest HR should be applied for determination of the QT.

AB - OBJECTIVE: Prolonged Q-T interval (QT) has been reported in patients with cirrhosis who also exhibit profound abnormalities in vasoactive peptides and often present with elevated heart rate (HR). The aim of this study was to relate QT to the circulating level of endothelins (ET-1 and ET-3) and calcitonin gene-related peptide (CGRP) in patients with cirrhosis. In addition, we studied problems with HR correction of QT. MATERIAL AND METHODS: Forty-eight patients with cirrhosis and portal hypertension were studied during a haemodynamic investigation. Circulating levels of ETs and CGRP were determined by radioimmunoassays. Correction of QT for HR above 60 beats per min was performed using the methods described by Bazett (QT(C)) and Fridericia (QT(F)). RESULTS: Prolonged QT(C) (above 440 ms), found in 56% of the patients, was related to the presence of significant portal hypertension and liver dysfunction (p < 0.05 to 0.001), but not to elevated ET-1, ET-3 or CGRP. When corrected according to Bazett, QT(C) showed no significant relation to differences in HR between patients (r = 0.07, ns). QTF showed some undercorrection of HR (r = -0.36; p < 0.02). During HR variation in the individual patient, QT(C) revealed a small but significant overcorrection (2.6 ms per heartbeat per min; p < 0.001). This value was significantly (p < 0.02) smaller with QTF (1.2 ms per heartbeat per min). CONCLUSIONS: The prolonged QT(C) in cirrhosis is related to liver dysfunction and the presence of portal hypertension, but not to the elevated powerful vasoconstrictor (ET-1) or vasodilator (CGRP, ET-3) peptides. The problems with correction of the QT for elevated HR in cirrhosis are complex, and the lowest HR should be applied for determination of the QT.

U2 - http://dx.doi.org/10.1080/00365510601182634

DO - http://dx.doi.org/10.1080/00365510601182634

M3 - Journal article

VL - 67

SP - 643

EP - 653

JO - Scandinavian Journal of Clinical & Laboratory Investigation

JF - Scandinavian Journal of Clinical & Laboratory Investigation

SN - 0036-5513

IS - 6

ER -

ID: 34106344